Colon Cancer Clinical Trial

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Summary

This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a high dietary fiber formula that is developed based on research findings that have shown that high fiber diets can help maintain healthy bacteria in the gut and improve gut function. Giving NBT-NM108 to patients with colon cancer receiving chemotherapy may help relieve or lessen diarrhea symptoms and lead to improved tolerance of the chemotherapy drug, irinotecan.

View Full Description

Full Description

PRIMARY ENDPOINT:

Dose Intensity of Irinotecan administered (mg/m2/week)

SECONDARY ENDPOINTS:

Reduction in % Patients Needing Dose Modification for Diarrhea
Toxicity Grade of diarrhea
Response Rate
Time to Progression-free survival

EXPLORATORY ENDPOINTS:

16S rRNA gene sequencing to reveal changes of the gut microbiota including institution of foundation guilds and restoration of healthy microbiome
Short chain fatty acids analysis (promotion of acetic and butyric acid production)
Markers for gut inflammation such as fecal lipocalin 2
Gut barrier function test to see if the restoration of healthier gut microbiota would improve gut barrier function.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Biopsy proven and metastatic colon cancer
Candidate for Second-line or later line therapy with irinotecan-based chemotherapy regimen with starting dose of irinotecan at 180 mg/m2 q2w.

Participants who have had prior irinotecan will be eligible if they are off irinotecan for at least three months and stools have returned to baseline consistency.

Performance Status (PS) 0-1
Lab values as acceptable for trials: Absolute Neutrophil Count( ANC) >1500/uL; Creatinine < 1.5 x Upper Limit of Normal (ULN); Transaminases < 5x ULN; Bilirubin < 1.5 x ULN; Albumin > 3.0 g/dL
No known UGTA1A* genotype

Exclusion Criteria

Grade two diarrhea or greater (4-6 movements per day over baseline)
Inability to take oral supplements
Current antibiotic therapy
Baseline grade 3-4 diarrhea Participants with grade two diarrhea should undergo stool evaluation with stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea. They will be eligible if this evaluation shows no infection.
History of the following infections and/or disease which could lead to diarrhea:
History of prior positive gastrointestinal biopsy, gastrointestinal culture, or stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia, Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea unless fully treated with at least three months normal stool.
History of ulcerative colitis, Crohn's disease, celiac sprue (gluten-enteropathy), chronic pancreatitis, malabsorption, or any other gastrointestinal disease associated with diarrhea.

Study is for people with:

Colon Cancer

Phase:

Phase 2

Estimated Enrollment:

42

Study ID:

NCT05296681

Recruitment Status:

Recruiting

Sponsor:

Howard S. Hochster, MD

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Trinitas Hospital and Comprehensive Cancer Center
Elizabeth New Jersey, 07202, United States More Info
Howard S Hochster, MD
Contact
732-253-5618
[email protected]
Robert Wood Johnson University Hospital, Hamilton
Hamilton New Jersey, 08690, United States More Info
Howard S Hochster, MD
Contact
732-235-2465
[email protected]
Monmouth Medical Center
Lakewood New Jersey, 08701, United States More Info
Howard Hochster, MD
Contact
732-235-2465
[email protected]
Cooperman Barnabas Medical Center
Livingston New Jersey, 07039, United States More Info
Howard S Hochster, MD
Contact
732-235-2465
[email protected]
Robert Wood Johnson University Hospital
New Brunswick New Jersey, 08901, United States More Info
Howard S Hochster, MD
Contact
732-235-5912
[email protected]
Liping Zhao, MD
Contact
(848) 932-5675
[email protected]
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States More Info
Howard S. Hochster
Contact
732-253-5618
[email protected]
Howard S. Hochster
Principal Investigator
The Cancer Center
Newark New Jersey, 07103, United States More Info
Howard S Hochster, MD
Contact
732-235-2465
[email protected]
Newark Beth Israel Medical Center
Newark New Jersey, 07112, United States More Info
Howard Hochster, MD
Contact
732-235-2465
[email protected]
Robert Wood Johnson University Hospital, Somerset
Somerville New Jersey, 08876, United States More Info
Howard S Hochster, MD
Contact
732-235-2465
[email protected]
Community Medical Center
Toms River New Jersey, 08753, United States More Info
Howard S Hochster, MD
Contact
732-235-2465
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 2

Estimated Enrollment:

42

Study ID:

NCT05296681

Recruitment Status:

Recruiting

Sponsor:


Howard S. Hochster, MD

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.